Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed glioblastoma multiforme and/or anaplastic astrocytoma
• •* Supratentorial tumor
• •* No well-differentiated astrocytoma or glioma with oligodendroglial component
• •* No multifocal glioma
• •Has undergone surgery within the past 6 weeks
• •No recurrent glioblastoma multiforme
• •PATIENT CHARACTERISTICS:
• •ECOG performance status 0-2
• •Neurological functional status 0-2
• •Life expectancy \> 12 weeks
• •ANC ≥ 1,200/mm³
• •Platelet count ≥ 100,000/mm³
• •Hemoglobin ≥ 9 g/dL
• •Serum creatinine ≤ 1.5 times upper limit of normal (ULN)
• •Blood urea nitrogen ≤ 1.5 times ULN
• •Total and direct bilirubin ≤ 3 times ULN
• •AST and ALT ≤ 3 times ULN
• •Alkaline phosphatase ≤ 3 times ULN
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for 3 months after study completion
• •No other malignancies within the past 3 years, except for carcinoma in situ of the cervix or nonmelanoma skin cancer
• •No acquired immune deficiency syndrome (AIDS)
• •No major medical illness or psychiatric impairment that would preclude study compliance
• •PRIOR CONCURRENT THERAPY:
• •No prior radiotherapy to the head and neck
• •No other concurrent therapy for the tumor